The Role of Adjuvants in the Application of Viral Vector Vaccines
Adjuvants are formulated in conventional vaccines to ensure immune recognition and the subsequent development of innate and/or adaptive immune responses. A principal advantage of using a viral vector is that no adjuvant is required as the vector alone can
- PDF / 5,766,700 Bytes
- 232 Pages / 504.63 x 737.01 pts Page_size
- 36 Downloads / 178 Views
al Vectors in Veterinary Vaccine Development A Textbook
Viral Vectors in Veterinary Vaccine Development
Thiru Vanniasinkam • Suresh K. Tikoo • Siba K. Samal Editors
Viral Vectors in Veterinary Vaccine Development A Textbook
Editors Thiru Vanniasinkam School of Biomedical Sciences Charles Sturt University Wagga Wagga, NSW, Australia
Suresh K. Tikoo VIDO-InterVac & School of Public Health University of Saskatchewan Saskatoon, SK, Canada
Siba K. Samal Department of Veterinary Medicine University of Maryland, College Park College Park, MD, USA
ISBN 978-3-030-51926-1 ISBN 978-3-030-51927-8 https://doi.org/10.1007/978-3-030-51927-8
(eBook)
# Springer Nature Switzerland AG 2021 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Switzerland AG. The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Foreword
A viral vector vaccine consists of a nonpathogenic virus (the vector) that expresses protective antigen(s) of one or more heterologous pathogens. The pathogen gene sequence (typically encoding surface protein) is engineered by recombinant DNA methods to be inserted into the vector genome and expressed as part of the vector’s transcriptional program. Following administration, a viral vector vaccine infects cells in the vaccine recipient. Some vectors are capable of limited vector replication in the recipient. Others are designed to be replication-defective and are restricted to a single cycle of infection. As described in this concise and very useful book, the viral vector vaccine approach is innovative and multifaceted, has resulted in a number of successful commercial veterinary vaccines to date, and has tremendous promise for further development. The first demonstration of the efficacy of a viral vector vaccine was in 1983 when a recombinant vaccinia virus ex
Data Loading...
